tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Rhythm Pharmaceuticals price target lowered to $140 from $141 at Canaccord
PremiumThe FlyRhythm Pharmaceuticals price target lowered to $140 from $141 at Canaccord
6d ago
Rhythm announces additional data from Phase 3 trial of setmelanotide
Premium
The Fly
Rhythm announces additional data from Phase 3 trial of setmelanotide
7d ago
Rhythm Pharmaceuticals price target raised to $143 from $140 at Guggenheim
Premium
The Fly
Rhythm Pharmaceuticals price target raised to $143 from $140 at Guggenheim
9d ago
Rhythm Pharmaceuticals: Imcivree Momentum and Bivamelanotide Pipeline Catalysts Underpin Buy Rating and $130 Target
PremiumRatingsRhythm Pharmaceuticals: Imcivree Momentum and Bivamelanotide Pipeline Catalysts Underpin Buy Rating and $130 Target
10d ago
Rhythm Pharmaceuticals reports Q4 EPS (73c), consensus (78c)
Premium
The Fly
Rhythm Pharmaceuticals reports Q4 EPS (73c), consensus (78c)
10d ago
Rhythm Pharmaceuticals reports Q4 EPS (73c), consensus (78c)
Premium
The Fly
Rhythm Pharmaceuticals reports Q4 EPS (73c), consensus (78c)
10d ago
Rhythm Pharmaceuticals price target raised to $125 from $123 at H.C. Wainwright
PremiumThe FlyRhythm Pharmaceuticals price target raised to $125 from $123 at H.C. Wainwright
2M ago
Rhythm Pharmaceuticals price target raised to $145 from $140 at BofA
Premium
The Fly
Rhythm Pharmaceuticals price target raised to $145 from $140 at BofA
2M ago
Rhythm Pharmaceuticals: Raising Revenue Forecasts and Price Target on Strengthening BBS Growth and Clear aHO Catalyst Path
Premium
Ratings
Rhythm Pharmaceuticals: Raising Revenue Forecasts and Price Target on Strengthening BBS Growth and Clear aHO Catalyst Path
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100